Friday, November 22, 2024

Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance

Related stories

Capgemini, Mistral AI & Microsoft Boost Generative AI

Capgemini announced a global expansion of its Intelligent App...

Rackspace Launches Adaptive Cloud Manager for Growth

Rackspace Technology®, a leading hybrid, multicloud, and AI technology...

Theatro Launches GENiusAI to Boost Frontline Productivity

Theatro, a pioneer in voice-controlled mobile communication technology, is...

Denodo 9.1 Boosts AI & Data Lakehouse Performance

Latest release adds an AI-powered assistant, an SDK to...

Health Catalyst Launches AI Cyber Protection for Healthcare

Health Catalyst, Inc., a leading provider of data and...
spot_imgspot_img

Transformative, instrument-free solution for single cell RNA sequencing updated with improved sensitivity, faster workflow

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products. Available to ship in mid-March, Evercode Whole Transcriptome version 3 kits offer researchers a more streamlined workflow, more flexible and higher throughput fixation, and optimized reagents for improved sensitivity in gene detection.

With the new version, customers will enjoy a more streamlined and flexible workflow, helping them move from samples to results more quickly. These enhancements are delivered while significantly improving upon the previous version’s sensitivity and library complexity, giving researchers higher biological resolution and insight into their samples.

Parse customers already rely on the utility of Evercode fixation, which enables them to fix cells or nuclei when they become available, store them for up to six months, and then sequence them when ready. Fixation is ideal for time course studies or for the removal of batch effects when samples aren’t available at the same time.

Also Read: For the First Time, Quantum-Enhanced Generative AI Generates Viable Cancer Drug Candidates

With the version 3 chemistry, customers now have the option of fixing up to 96 samples simultaneously in plate format, a valuable upgrade for applications involving high throughput drug screening or the profiling of patient samples from large cohorts.

“We’ve been listening to customer feedback and believe that with this new version, we’re providing researchers with tools that are unmatched in their sensitivity, scalability, and flexibility,” said Parse Biosciences co-founder and CTO Charlie Roco. “Our goal from the start has been to democratize single cell research by making it more accessible, and the scientific community’s response to Evercode has been overwhelmingly positive.”

The new chemistry is available for the entire Whole Transcriptome product line: WT Mini for experiments up to 10,000 cells or nuclei, WT for experiments up to 100,000 cells or nuclei, WT Mega for experiments up to 1,000,000 cells or nuclei, and Fixation for cells or nuclei.

SOURCE: Parse Biosciences

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img